Around one in nine Chesterfield adults still unvaccinated
Around one in nine adults in Chesterfield have yet to receive a Covid-19 vaccine, figures suggest – as the Government launches plans to offer booster shots in the autumn.
Prime Minister Boris Johnson has appealed to the millions of people across the UK who have not yet taken up the offer of a coronavirus vaccine to finally get the jab to help the country avoid tougher restrictions over the winter.
NHS England data shows 76,943 people aged 18 and over in Chesterfield had received a first dose of the vaccine by September 13.
But this means that 10,155 remain unvaccinated – around 11.7% of all adults in the area, based on the number of people on the National Immunisation Management Service.
Those aged 18-29 have the highest refusal rates in the area, with 22.9% yet to get a jab, followed by the 30-39 age bracket (19.9%).
A higher proportion of children aged 16 and 17 are unvaccinated (39.5%), but they were offered the jab much later than others.
At the other end of the scale, just 2.1% of those aged 80-89 have not received their first vaccine.
Around 10.8% of the UK population aged 16 and above have not taken up the offer of a Covid-19 vaccine.
As the Prime Minister launched his plan to “live” with the disease through the coming months, his chief scientific adviser Sir Patrick Vallance said getting vaccination levels up was the key to keeping case numbers down and maintaining lighter controls.
He said: “There are five million or so people who are eligible for vaccines now who haven’t been vaccinated.
“Trying to persuade those people it is the right thing to do to get vaccinated would make a significant difference.”
Mr Johnson said additional measures could include vaccine passports, as well as the return of face masks in public places and encouraging people to work from home.
However, he said the “priority” was to get everyone possible vaccinated, insisting that it was in their own interests to get protected.
The Government said that vaccine protection was holding up "very well" against the disease, but there was evidence that it was fading – particularly in those who are most vulnerable.